Can Progesterone Help You Get Pregnant? Honest Science

• Progesterone prepares and maintains the uterine lining after ovulation. It does not cause ovulation, improve egg quality, increase egg numbers, or help sperm reach the egg.
• The strongest evidence is for luteal-phase support in IVF and stimulated IUI cycles, where fertility medications disrupt the body's own progesterone.
• For early-pregnancy bleeding in a woman with one or more prior miscarriages, the PRISM trial supports vaginal progesterone (400 mg twice daily through 16 weeks).
• For natural conception in couples with normal ovulation and no recurrent loss, major guidelines (ASRM, ESHRE, NICE, FOGSI) do not recommend routine progesterone; the Cochrane evidence shows no clear benefit.
• Common Indian options include vaginal inserts (Susten, Endogest, Naturogest), Crinone gel, oral dydrogesterone (Duphaston) and injectable progesterone (Gestone); costs run roughly Rs 350-1500 per month.
• Progesterone is low-risk but should never replace a proper fertility workup. Always ask your doctor for the specific reason, expected benefit and planned duration.

Progesterone is the dominant hormone of the second half of your cycle, called the luteal phase. After What Ovulation Actually Means, the empty follicle on the ovary becomes a temporary gland called the corpus luteum ("yellow body"), which produces progesterone in rising amounts over the next several days. Its single overarching job is to prepare and maintain the uterine lining (endometrium) for a possible pregnancy. Every other effect, from breast tenderness to a higher body temperature, follows from this.

Under progesterone, the lining that estrogen built up in the first half of the cycle turns from a "proliferative" lining into a "secretory" one that can support an embryo. Glands start producing nutrient-rich secretions, blood vessels become more elaborate, and the lining grows thicker and more receptive. This peaks 6 to 10 days after ovulation, which is exactly when an embryo would arrive at the uterus to implant. The timing is not a coincidence.

If implantation does not happen, the corpus luteum runs its programmed lifespan of about 12 to 14 days and then fades. Progesterone falls sharply, the lining loses its support, and it sheds as your period. If implantation does happen, the embryo starts producing hCG (the pregnancy hormone), which tells the corpus luteum to keep going. The corpus luteum makes progesterone for the first 7 to 10 weeks, after which the placenta takes over, a handoff called the luteoplacental shift. This is why progesterone is sometimes continued through the first trimester in at-risk pregnancies.

Progesterone also produces the familiar luteal-phase signs: mild sedation and mood shifts (through brain GABA receptors), breast tenderness, bloating and slower digestion, and a sustained rise in temperature of about 0.3 to 0.5 degrees Celsius, the basis of basal body temperature charting. When progesterone is supplemented, these same effects are sometimes mistaken for "side effects" when they are really just the hormone's normal signature.

Understanding this also makes clear what progesterone does not do. It does not trigger ovulation (the LH surge does that), does not improve egg quality (age and ovarian factors decide that), does not increase egg numbers, and does not directly affect sperm or how the fallopian tube moves the egg or embryo. Its role is downstream, in the uterus. Any claim that progesterone "boosts fertility" beyond supporting the lining overstates what the hormone can do.

Luteal phase deficiency (LPD) is the idea of a luteal phase that is too short, makes too little progesterone, or produces a lining that is inadequately developed for implantation. The concept dates to the 1940s and has been one of the most controversial diagnoses in reproductive medicine, partly because its definitions have shifted over decades and partly because the practical implications are often unclear. We cover this in depth in our dedicated guides to luteal phase defect and the short luteal phase in TTC.

Traditional definitions of LPD involve a luteal phase shorter than 10 days, a mid-luteal progesterone below a threshold (commonly 10 ng/mL around day 21 of a 28-day cycle, or 7 days after ovulation), or an endometrial biopsy showing development lagging by 2 or more days. None of these has proven reliable at separating women who will benefit from progesterone from those who will not.

The American Society for Reproductive Medicine (ASRM) has stated that LPD is not a clinically useful diagnosis in women trying to conceive naturally, because the criteria do not correlate well with pregnancy outcomes and because progesterone naturally pulses through the luteal phase. A single low reading may simply be a trough in that pulse, not genuinely inadequate production. Endometrial biopsy for dating is no longer recommended outside research because it is invasive, painful and unreliable. ESHRE and NICE take similar positions, urging caution against routine LPD diagnosis in naturally conceiving women.

What is universally accepted is that the luteal phase in assisted reproduction, particularly IVF and stimulated IUI, is often disrupted by the medications used. Stimulation drugs, GnRH suppression, the trigger injection and the egg-retrieval procedure all interfere with normal corpus luteum function, so it may make less progesterone and the lining may be less receptive. This is the clearest, most evidence-based reason to supplement.

In naturally conceiving couples, the case is much weaker. A Cochrane review of progesterone for subfertility found no clear benefit, and ASRM and ESHRE advise against routine supplementation. Yet in everyday Indian practice progesterone is often prescribed for unexplained infertility, for couples trying for several months, or after one or two losses. This reflects low cost, low risk, patient demand for some action, and the reflex to "do something." It is not harmless if it delays a proper diagnosis.

Luteal-phase progesterone in IVF is the most evidence-based use of the hormone in all of fertility care. Every standard IVF protocol in India includes it, consistent with ASRM, ESHRE, FOGSI and NICE recommendations.

The reason is straightforward: the drugs used to control an IVF cycle disrupt the corpus luteum. GnRH agonist or antagonist medications suppress the pituitary LH that would normally support the corpus luteum after retrieval. The egg-retrieval procedure removes many of the cells that would have formed the corpus luteum. And the very high estrogen levels during stimulation alter normal feedback. Without supplementation, the luteal phase often has subnormal progesterone and a higher risk of implantation failure.

The standard protocol starts progesterone on the day of, or day after, egg retrieval and continues until the pregnancy test about two weeks later. If positive, it usually continues through 8 to 10 weeks, by which point the placenta has taken over. If negative, it is stopped and the cycle ends.

The usual form in IVF is vaginal, though intramuscular progesterone in oil (PIO) was historically standard and is still used in some Indian clinics. Vaginal progesterone delivers the hormone straight to the endometrium through a first-pass uterine effect, giving high local concentration with relatively low blood levels. Common Indian vaginal options include Susten 200/400 mg inserts (Sun Pharma, ~Rs 400-700/month), Endogest 200 mg inserts (Cipla, ~Rs 350-600/month), Naturogest 200 mg inserts (Zydus, ~Rs 400-700/month) and Crinone 8% gel (Merck, ~Rs 800-1500/month). Inserts are typically dosed 200 mg two or three times daily; Crinone is one applicator daily.

Injectable PIO (Gestone, ~Rs 100-300/ampoule) achieves the most reliable serum levels but the injections are notoriously uncomfortable and can cause local irritation and sterile lumps. Modern practice has largely shifted to vaginal forms because they are better tolerated with equivalent outcomes, though some clinics still use PIO for specific frozen-embryo-transfer protocols.

Oral micronised progesterone is available but is generally not preferred for IVF luteal support, because it undergoes heavy first-pass liver metabolism that converts much of it to inactive metabolites.

IUI cycles have weaker but still meaningful evidence, especially when gonadotropin stimulation is used. The luteal disruption is less than in IVF, but adding progesterone modestly improves pregnancy rates in stimulated IUI. Natural-cycle IUI without stimulation has less clear evidence, though many Indian clinics still prescribe a course as a precaution. Dosing mirrors IVF: vaginal progesterone 200-400 mg twice daily starting the day after IUI, continued for two weeks to the pregnancy test.

Once pregnancy is confirmed in an IVF or IUI cycle, progesterone is usually continued through 10 to 12 weeks. This is slightly more cautious than the biology strictly requires, but the small risk of stopping too early is felt to outweigh the cost. Some clinics taper the dose rather than stopping abruptly.

In couples trying to conceive naturally, without IVF or IUI, the evidence for progesterone is significantly weaker, and major guidelines are cautious. The Cochrane review found no clear benefit, and ASRM, ESHRE and FOGSI all advise against routine prescription in this group.

This sits awkwardly against common Indian practice, where progesterone is frequently prescribed for couples trying for several months, for unexplained infertility, for PCOS on natural conception, and after single early losses. The disconnect reflects low cost, low risk, patient demand for any helpful step, the difficulty of accepting "wait and see" in a high-anxiety context, and defensive medicine.

The situations with at least some supporting evidence are a genuinely diagnosed short luteal phase (consistently under 10 days from ovulation to next period across several tracked cycles) and women with PCOS ovulating with letrozole or clomiphene, where luteal support may help. Even here the evidence is modest and any benefit is small.

Before starting progesterone for natural conception, ask three questions. First, what is the specific clinical reason in my case? "Just to be safe" is not an evidence-based indication. Second, what is the expected benefit, and how will we know if it worked? Without a clear measure of success, you may feel obliged to continue indefinitely. Third, what are the ongoing costs and inconveniences? Vaginal progesterone can cause messy discharge and irritation, and a two-or-three-times-daily routine can be disruptive.

There is also a psychological cost. Many women on progesterone for natural conception feel they are "doing something," which is reassuring short-term but can delay more decisive steps. Three or four months on a treatment unlikely to be the limiting factor is time not spent on a thorough workup. The emotional load of TTC is real, and a placebo-equivalent treatment is not a substitute for answers.

The honest framing: natural-conception progesterone is a low-cost, low-risk option with weak evidence that may be reasonable to try for a defined period if you and your doctor agree, but it should not replace proper evaluation. A reasonable middle path is a defined three-month trial, then either continue if there is a clear change or stop and escalate to a fuller workup, including AMH and ovarian reserve testing, a day-2 hormone panel, transvaginal ultrasound, an HSG if indicated, and a semen analysis for the male partner.

It is also worth separating planned progesterone supplementation from progesterone given empirically after ovulation induction. The latter, particularly after clomiphene (which can have mild adverse effects on the endometrium and cervical mucus), is more justifiable than a vague prescription in a normally ovulating couple.

Recurrent miscarriage, defined as two or more consecutive losses, affects about 1 to 2 percent of couples and is one of the most emotionally devastating experiences in reproductive medicine. Progesterone has long been hypothesised to help, on the reasoning that some losses might be due to inadequate luteal support. The evidence has been mixed but has clarified meaningfully over the last decade.

The PROMISE trial (NEJM, 2015) randomised 836 women with unexplained recurrent miscarriage to vaginal progesterone or placebo from a positive test through 12 weeks. It found no overall benefit; live-birth rates were similar in both groups. This significantly downgraded the routine use of progesterone in recurrent miscarriage for several years.

The PRISM trial (NEJM, 2019) took a different approach, randomising 4,153 women with early-pregnancy bleeding to vaginal progesterone or placebo. The overall trial again found no significant benefit, but the prespecified subgroup of women who had bleeding and a history of one or more prior miscarriages did show a possible benefit. The effect was modest, roughly a 5 percentage-point absolute increase in live-birth rate in that higher-risk subgroup, but meaningful.

Based on PRISM, NICE updated its guidance in 2021 to support vaginal progesterone for women with bleeding in early pregnancy who have had at least one prior miscarriage. The regimen is vaginal micronised progesterone 400 mg twice daily, from the time bleeding presents through 16 weeks. NICE did not recommend progesterone for women without bleeding even with a history of recurrent loss, though it noted some may still choose it given the low harm.

ASRM, ESHRE and FOGSI broadly support this position with minor variation. ASRM notes progesterone can be a "reasonable empirical therapy" in recurrent miscarriage even outside the bleeding scenario; ESHRE is more cautious, favouring the bleeding-with-prior-loss situation; FOGSI endorses the bleeding-with-prior-loss indication and is broadly supportive of empirical use given Indian cost-benefit considerations.

The PRISM-style protocol uses vaginal micronised progesterone such as Susten 400 or Endogest 400 mg twice daily, or Crinone 8% gel once daily, from bleeding presentation through 16 weeks. It is generally well tolerated, with an added cost of roughly Rs 800 to Rs 2000 per month for this defined period.

For recurrent miscarriage without current bleeding, the position is more nuanced. PROMISE does not support routine prophylactic progesterone, but some Indian specialists offer it after an honest discussion of the equivocal evidence. Crucially, progesterone should not delay evaluation. A woman who has had two or three losses should be undergoing a structured workup, which typically includes karyotyping of both partners (Rs 5,000-15,000 each), antiphospholipid antibody testing (lupus anticoagulant, anticardiolipin, beta-2 glycoprotein), thyroid function (because thyroid problems affect fertility), prolactin, AMH, transvaginal ultrasound of the uterus, an HSG or saline sonography for the cavity, and sometimes a thrombophilia panel. Treatable causes come first; progesterone is a supplemental measure at best. FOGSI specifically frames it as one element of a broader plan, not a standalone cure. Note too that a very early loss known as a chemical pregnancy is common and usually not preventable with progesterone.

The Indian progesterone market includes a wide range of brands, formulations and prices. Knowing the options helps you understand what you are being prescribed and what it should cost.

Vaginal micronised progesterone is the most common form for fertility and early-pregnancy support. Major brands are Susten (Sun Pharma) in 100/200/400 mg inserts (~Rs 400-700/month); Endogest (Cipla) in 100/200/400 mg inserts (~Rs 350-600/month); Naturogest (Zydus) in 100/200/400 mg inserts (~Rs 400-700/month); Microgest (Sun Pharma) in 100/200 mg inserts (~Rs 300-500/month); plus several smaller-brand generics at similar prices.

Crinone 8% vaginal gel (Merck) uses a bioadhesive base for prolonged vaginal contact, costing about Rs 800-1500/month for once-daily dosing. Some prefer the once-daily convenience; others find the gel messier than inserts. Both achieve similar uterine progesterone levels with no clear clinical superiority of one over the other.

Oral micronised progesterone (Susten oral, Endogest oral, Naturogest oral, Microgest oral, in 100/200 mg capsules, ~Rs 300-600/month) is preferred for non-fertility indications such as menstrual disorders, perimenopausal management and hormone replacement. Heavy first-pass liver metabolism is why it is not the preferred form for fertility luteal support, where high local uterine levels are needed.

Injectable progesterone in oil (PIO) is available as Gestone (Ferring, ~Rs 100-300 per 50/100 mg ampoule) and various generics. It is given as a deep intramuscular injection, usually in the gluteal muscle, often self-administered after training. The injections are painful and can cause sterile lumps and local pigmentation, but they give the most reliable serum levels. PIO is still used in some IVF protocols, particularly hormone-replacement frozen embryo transfer.

Synthetic progestins are a different class often confused with natural progesterone. These include dydrogesterone (Duphaston, ~Rs 200-400/month), medroxyprogesterone acetate (Provera, ~Rs 100-300/month) and norethindrone (~Rs 100-300/month). Of these, dydrogesterone is closest to natural progesterone in action and is widely used in India for luteal support and miscarriage indications; the LOTUS trials showed it was non-inferior to vaginal micronised progesterone in IVF, with the convenience of oral dosing. Medroxyprogesterone and norethindrone are used for menstrual disorders and contraception, not fertility support.

When comparing prices, consider the total over the planned duration, not just the monthly cost. A standard IVF luteal protocol may run from about Rs 1000 for a negative cycle to Rs 5000-7000 for a positive cycle continued through the first trimester. A PRISM-style protocol over 14-15 weeks is roughly Rs 4000-12000 depending on brand. These are usually a small fraction of overall fertility-treatment cost.

Availability is generally good. All major brands are stocked at Apollo Pharmacy, MedPlus, Wellness Forever, Tata 1mg, PharmEasy and Netmeds, and most independent pharmacies in metro and tier-2 cities. In smaller towns, substituting an equivalent brand of the same form and dose is usually fine with your specialist's confirmation.

The choice between vaginal, oral and injectable progesterone depends on the indication, your preferences, your specialist's protocol and practical factors like cost and tolerability. Each form has trade-offs.

Vaginal progesterone is the most-used form for fertility luteal support. Its advantages are direct delivery to the endometrium (first-pass uterine effect), high local concentration with low blood levels (fewer systemic side effects), a strong evidence base in IVF and IUI, and good tolerability. Disadvantages include discharge that can be messy and stain underwear, occasional irritation or itching, the need for two or three doses a day for inserts, and lying down for a few minutes after insertion to reduce leakage.

Oral micronised progesterone is convenient (a capsule with water, no vaginal manipulation) and reasonably priced. The downsides are heavy first-pass liver metabolism, more pronounced systemic effects (drowsiness, dizziness, mood changes) and a weaker evidence base for fertility luteal support. It is generally preferred for non-fertility indications instead.

Injectable progesterone in oil (PIO) gives the most reliable serum levels and the longest historical track record in IVF, but the injections are painful (the oil base needs a large-bore needle), can cause sterile lumps and pigmentation, and disrupt sleep from injection-site discomfort. Modern IVF has largely moved away from routine PIO, though some specialists still prefer it for specific protocols.

Dydrogesterone, an oral progestin closely related to natural progesterone, occupies an interesting middle position: oral convenience without the heavy first-pass loss that limits oral micronised progesterone, reliable systemic levels, good tolerability and non-inferiority to vaginal micronised progesterone in the LOTUS IVF trials. Duphaston costs roughly Rs 200-400/month and is widely used in Indian practice for both IVF luteal support and miscarriage indications.

For most patients, the practical decision for IVF and IUI is between vaginal micronised progesterone and oral dydrogesterone. Both are evidence-based, well tolerated and widely available, and the choice often comes down to preference: those who dislike vaginal inserts may prefer oral dydrogesterone, while those who get drowsy or moody on oral progestins may prefer vaginal. Some protocols combine both for redundancy in high-risk cases.

For early-pregnancy bleeding with prior miscarriage (the PRISM indication), vaginal micronised progesterone 400 mg twice daily has the most direct trial evidence, and most Indian specialists follow it. Some use dydrogesterone here based on its miscarriage-prevention evidence, though the direct PRISM-style evidence is less robust.

Do not switch between forms without specialist guidance, especially mid-cycle or mid-pregnancy, because different forms achieve different levels and an abrupt switch can cause progesterone dips. If a form is genuinely intolerable, discuss alternatives rather than self-switching or stopping.

Progesterone is generally well tolerated, but side effects can be uncomfortable and limiting for some. Knowing what to expect helps you persist when treatment is genuinely needed.

The most common effects of vaginal progesterone are discharge, occasional itching or irritation, and a sensation of fullness. Discharge is usually whitish or creamy and can be substantial; many women use panty liners. Irritation can be reduced by inserting at bedtime to limit daytime discomfort. Persistent itching or burning may signal a yeast infection, since elevated progesterone and an altered vaginal environment can predispose to candida; this should be evaluated and treated with antifungal medication if confirmed.

Systemic effects (in any form) include drowsiness, dizziness, mild low mood or mood swings, breast tenderness, bloating, mild headache and occasional nausea. These are usually mild and resolve when supplementation stops. Drowsiness is most pronounced with oral micronised progesterone and is best managed by dosing at bedtime. Breast tenderness and bloating are essentially the normal luteal-phase symptoms exaggerated by supplementation.

Mood effects deserve specific attention. Some women feel significant low mood, irritability or anxiety, particularly on oral or injectable forms, through progesterone metabolites (such as allopregnanolone) acting on brain GABA receptors. Women with a history of PMDD, depression or anxiety are more likely to feel pronounced effects. If mood changes are severe or interfere with daily life, contact your specialist about switching form or adjusting dose. Vaginal progesterone tends to have milder mood effects due to lower systemic absorption.

Injectable PIO has injection-specific effects: pain at the site, local pigmentation, small lumps or sterile abscesses, occasional allergy to the oil carrier, and disrupted sleep. Proper technique helps: rotate sites, inject deep and slowly, use a warm compress before and massage after. Switching to vaginal forms is usually possible if PIO becomes intolerable, unless a protocol specifically requires it.

Allergic reactions are rare but possible: itching, hives, rash, or in severe cases swelling or breathing difficulty. Any suspected reaction should prompt stopping and immediate contact with your specialist; switching brand or form may be tolerated.

Vaginal infections (yeast and bacterial vaginosis) are slightly more common during vaginal supplementation. Treatment is the same as for non-progesterone-related infections. Avoiding tight clothing, changing underwear daily and good genital hygiene help.

Important: spotting or light bleeding can occur and is usually not concerning, especially in early pregnancy where progesterone is supporting a threatened miscarriage. But any heavy bleeding, severe pain or sudden change in symptoms needs immediate medical attention. Do not stop progesterone abruptly during early pregnancy without specialist guidance, as sudden withdrawal can undermine the supplementation.

Long-term safety is well established. Decades of clinical use and multiple trials have not identified significant long-term risks of vaginal or oral progesterone in fertility treatment or early pregnancy. The hormone is bioidentical to your own progesterone, and the body clears it quickly when supplementation stops.

Distilled into a practical framework, progesterone has clear benefit in some scenarios, uncertain benefit in others, and none in still others. The honest answer to "will progesterone help me get pregnant?" depends on which scenario describes you.

Having a clear conversation about progesterone is one of the highest-leverage things you can do to ensure evidence-based care. It takes a few specific questions and a willingness to push gently for clear answers.

• ASRM Practice Committee: Current clinical irrelevance of luteal phase deficiency
• NICE NG126: Ectopic pregnancy and miscarriage — progesterone for threatened miscarriage
• Coomarasamy A et al. PRISM trial: Progesterone in women with bleeding in early pregnancy (NEJM 2019)
• Coomarasamy A et al. PROMISE trial: Progesterone in recurrent miscarriages (NEJM 2015)
• Cochrane Review: Progesterone for women with subfertility
• ESHRE Guideline: Recurrent pregnancy loss
• FOGSI (Federation of Obstetric and Gynaecological Societies of India) — Good Clinical Practice Recommendations